Heat Shock Protein 70 (Hsp70) Suppresses RIP1-Dependent Apoptotic and Necroptotic Cell Death

Sharan R. Srinivasan1, Laura C. Cesa1, Xiaokai Li4, Olivier Julien4, Min Zhuang4, Hao Shao4, Jooho Chung3, Ivan Maillard3, James A. Wells4, Colin Duckett2, and Jason E. Gestwicki4

1Program in Chemical Biology, 2Department of Pathology, 3The Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109; 4Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA 94158

Running Title: Hsp70 inhibition Activates Cell Death

*Correspondence:
Jason E. Gestwicki
University of California at San Francisco
675 Nelson Rising Lane
San Francisco, CA 94158.
415-502-7121
jason.gestwicki@ucsf.edu
Abstract

Heat shock protein 70 (Hsp70) is a molecular chaperone that binds to "client" proteins and protects them from protein degradation. Hsp70 is essential for the survival of many cancer cells, but it is not yet clear which of its clients are involved. Using structurally distinct chemical inhibitors, we found that many of the well-known clients of the related chaperone, Hsp90, are not strikingly responsive to Hsp70 inhibition. Rather, Hsp70 appeared to be important for the stability of the RIP1 (RIPK1) regulators: cIAP1/2 (BIRC1 and BIRC3), XIAP, and cFLIP\_S/L (CFLAR). These results suggest that Hsp70 limits apoptosis and necroptosis pathways downstream of RIP1. Consistent with this model, MCF7 breast cancer cells treated with Hsp70 inhibitors underwent apoptosis, while co-treatment with z-VAD.fmk switched the cell death pathway to necroptosis. In addition, cell death in response to Hsp70 inhibitors was strongly suppressed by RIP1 knockdown or inhibitors. Thus, these data indicate that Hsp70 plays a previously unrecognized and important role in suppressing RIP1 activity.

Implications

These findings clarify the role of Hsp70 in pro-survival signaling and suggest IAPs as potential new biomarkers for Hsp70 inhibition.

Introduction

Elevated expression of Hsp70 correlates with poor survival and resistance to chemotherapeutics\(^1\)-\(^4\). Hsp70 is generally thought to inhibit both the extrinsic and intrinsic pathways of apoptosis\(^5\) by protecting important “clients”, such as the oncoproteins Raf-1 and Akt-1, from degradation\(^6\)-\(^8\). However, this model is largely based on analogy to the related chaperone, Hsp90\(^9\)-\(^10\). Inhibitors of Hsp90 are well-known to release clients from that chaperone, leading to protein degradation and, ultimately,
apoptotic cell death\textsuperscript{11,12}. It is not clear whether Hsp70’s activity is restricted to these “Hsp90-like” functions or if it plays a broader or even parallel role.

The molecular roles of Hsp70 in cancer have been elusive, in part, because of a lack of selective chemical inhibitors. A number of recent reports have created the first generation of Hsp70 inhibitors, including VER-155008\textsuperscript{8}, MAL3-101\textsuperscript{13} and JG-98\textsuperscript{14}. These molecules belong to distinct chemical families and have non-overlapping binding sites\textsuperscript{15}. For example, JG-98 is an allosteric inhibitor that binds tightly to a deep pocket\textsuperscript{16} that is conserved in members of the Hsp70 family\textsuperscript{14}. Importantly, JG-98 and its analogs have been found to be relatively selective for members of the Hsp70 family, based on results from pulldowns\textsuperscript{17}, over-expression and point mutations\textsuperscript{18-21}. The mechanism of JG-98 is to block a key allosteric transition in Hsp70 that favors degradation of some Hsp70-bound clients\textsuperscript{19,21}. Other compounds bind different locations and have distinct mechanisms\textsuperscript{22}. For example, VER-155008 competes for binding of nucleotide to Hsp70\textsuperscript{8} and MAL3-101 binds to a distinct allosteric site\textsuperscript{23}. Although JG-98 is relatively non-toxic (EC\textsubscript{50} > 20 µM) to normal mouse embryonic fibroblasts (MEFs), it has anti-proliferative activity (EC\textsubscript{50} ~ 400 nM) in multiple cancer cell lines\textsuperscript{14} and its analogs kill tamoxifen-resistant cells\textsuperscript{24}. Similar selectivity for transformed cells is observed using Hsp70 inhibitors belonging to other chemical series\textsuperscript{8,25}. The consistency of this result is important because parallel activity across chemically distinct molecules often suggests that the activity is mediated by the intended target. Based on all of these recent findings, we envisioned JG-98 and other new Hsp70 inhibitors as promising chemical tools for better understanding the chaperone’s specific molecular roles in cancer.

Using multiple, structurally distinct Hsp70 inhibitors, we found that Hsp90 clients, such as Akt or Raf1, are only weakly degraded after treatment. Rather, the stability of the RIP1 regulators, IAP1/2, XIAP, and cFLIP\textsubscript{S/L}, seemed sensitive to Hsp70 activity. Indeed, in MDA-MB-231 breast cancer cells, the kinetics of cell death correlated better with the loss of the RIP1 regulators than with degradation of Hsp90 clients. Consistent with a role in limiting RIP1 activation, treatment with Hsp70 inhibitors led to apoptotic cell death, but co-administration with z-VAD-fmk switched the cells to a necroptotic
pathway. Further, cell death in response to Hsp70 inhibitors required RIP1 activity, as shown using RIP1 knockdown and selective RIP1 kinase inhibitors. Thus, although Hsp70 is likely to have multiple clients, its activity on RIP1 seems to be especially important in cell survival. These findings may help guide the selection of Hsp70-selective biomarkers and potentially accelerate the discovery of clinical candidates.

Materials and Methods:

Reagents and Antibodies. Inhibitors: The following reagents were purchased from Sigma-Aldrich: Necrostatin-1, Bortezomib; Enzo: z-VAD.fmk; Millipore: Necrosulfonamide; LC Labs: 17-DMAG; StressMarq: VER-155008; and Teva Pharmaceuticals: Etoposide. JG-98 was synthesized and characterized as previously described14. All compounds were suspended in DMSO and the final solvent concentration in the assays was held to 1%. Antibodies: The following antibodies were purchased from Enzo: Hsp72 (C92F3A-5), XIAP (ADI-AAM-050), c-IAP1 (ALX-803-335), Caspase-8 (ALX-804-429); SCBT: GAPDH (sc-32233), Hsp90 (sc-7947), Raf-1 (sc-133), Caspase-8 (sc-6136), anti-rat (sc-2006), goat IgG (sc-2028); CellSignal: Akt-1 (2967), Cleaved Caspase-3 (9664), c-IAP2 (3130); BD Pharmingen: RIP1 (610459), Cdk4 (559693), cytochrome c (556433), Bcl-xL (610746); Molecular Probes: COXIV (A21347); Alexis: FLIP (ALX-804-428); Millipore: Smac (567365).

Tissue Culture. MDA-MB-231 WT cells were maintained in DMEM (Invitrogen), supplemented with 10% Fetal Bovine Serum (FBS), 1% Penicillin-Streptomycin, and non-essential amino acids. Jurkat cells were grown in RPMI 1640 (Corning), supplemented with GlutaMax. MDA-MB-231 and Jurkat cells overexpressing Bcl-xL and RIP1 knockout Jurkat cells were all created as previously described26.

Cell Line Authentication. All cell lines were purchased from American Type Culture Collection (ATCC) and experiments performed on cells that were passaged less than 20 times.
Cell Growth Assays. Cell growth was analyzed using either the MTT or Cell Titer Glo assays as previously described\(^\text{14}\) or trypan blue exclusion, as indicated in the text. To supplement these assays, light microscopy, annexin and Hoescht staining were used to report on cell viability. \(EC_{50}\) values were calculated from 12-point concentration curves, using serial 2-fold dilutions. When noted, cells were pre-treated with z-VAD.fmk (40 \(\mu\)M), Necrostatin-1 (20 \(\mu\)M), Necrosulfonamide (20 \(\mu\)M), or a combination for 1 hour before addition of designated drug.

Flow Cytometry. MDA-MB-231 cells were detached using Accutase (BD Biosciences) and washed with PBS before staining with annexinV-APC (BD Biosciences) for 15 minutes at room temperature. Cells were washed again with PBS before addition of DAPI (100 \(\mu\)g/mL) immediately before analysis.

Immunoprecipitations. Ripoptosome. Cells were pre-treated with z-VAD.fmk (20 \(\mu\)M) to limit cleavage of RIP1. Following compound treatments, cells were incubated for 24 hours before proceeding with lysis, immunoprecipitation, and western blots, as previously described\(^\text{27}\). Hsp70 binding to XIAP. MCF-7 cell extracts were prepared in chilled lysis buffer (50 mM Tris (pH 8), 150 mM NaCl, 1 mM ATP, 10 mM KCl, 5 mM Mg(OAc)\(_2\), 1\% NP-40) supplemented with protease inhibitor cocktail (Roche Applied Science). The total protein concentration was adjusted to 5 mg of protein in 1 mL of cell extract. PureProteome Protein G magnetic beads (Millipore) were incubated with 6 \(\mu\)g of a specific antibody for Hsp70 (Santa Cruz Biotechnology) or XIAP (Enzo Life Sciences) or nonspecific mouse IgG (Santa Cruz Biotechnology) for 30 minutes at room temperature with mixing, followed by antibody crosslinking with bis(sulfosuccinimidyl) suberate (Thermo Scientific) for 1 hour at room temperature with mixing. The crosslinking reaction was quenched with 1 M Tris (pH 7.5) for 1 hour at room temperature with mixing. Equal 100 \(\mu\)L samples of cell lysate were each pre-cleared by incubation with 50 \(\mu\)L of protein G beads for 1 hour at room temperature with mixing. Protein complexes were immunoprecipitated by incubation of the pre-cleared lysate (1 mg total protein per IP) with 50 \(\mu\)L of antibody-crosslinked protein G beads for 1 hour at room temperature with mixing. The immunocomplexes were washed 3 times with 500
μL of wash buffer (PBS (pH 7.4), 0.1% Tween-20) and eluted with 0.1 M glycine (pH 2.6). Samples were run on a 10% Tris-glycine gel (Bio-Rad) and transferred to PVDF membrane (Thermo Scientific). Proteins were visualized by Western blot with antibodies against Hsp70 (1:1000, Santa Cruz Biotechnology) and XIAP (1:500, Enzo Life Sciences).

**Fluorescence and Light Microscopy.** Cells were visualized using an Olympus IX83 Inverted Microscope. Nuclear morphology was examined by Hoechst 33258 staining (Sigma). For each experiment, at least 10 individual frames were examined and representative panels chosen for presentation. For quantification, we manually counted 200 cells from three independent experiments.

**Proteolytic Profiling (“N-terminal Degradomics”).** Eight liters of T-cell leukemia Jurkat A cells were grown in four separate 3 L spinner flasks to a density of 0.8 x 10⁶ cells/mL (see below). The cells were then treated for 16 hours with 1) 10 µM JG98 alone, 2) 10 µM JG98 and 20 µM necrosulfamide (NSA), 3) 10 µM JG98 and 20 µM of cell permeable pan caspase inhibitor zVAD(OMe)-fmk, or 4) left untreated. For the combination treatments, the cells were pre-treated with NSA or zVAD for 1 hour prior to the addition of JG98. Cell growth was monitored using a Scepter cell counter (Millipore inc.) to estimate the amount of cell death and cell morphology changes monitored under a Zeiss Observer Z1 microscope to confirm the expected phenotype. Free N-termini were detected as previously described (see below). In short, cell lysates were collected and the cells lysed using 0.1% Trion X-100 (~0.8-1.2 x 10⁹ cells per sample), free N-termini biotinylated using a cleavable peptide ester (TEVest4B) and subtiligase, protein fragments captured on Neutravidin beads and trypsin-digested. Each sample was then fractionated by HPLC into 12 fractions, for a total of 48 LC-MS/MS injections on an Orbitrap Velos Pro (Thermo Scientific inc.). Peptide identification was performed using Protein Prospector (v. 5.10.15 or higher) (University of California, San Francisco). All spectra were searched using the full human SwissProt database (downloaded 2013/06/27) with random sequence database for false discovery rate determination. Search parameters included: fixed modification cysteine carbamidomethylation; variable
modifications N-terminal aminobutyric acid, methionine-loss (N-terminus) and methionine oxidation; up to one missed tryptic cleavages; C-terminal trypsin cleavage; non-specific cleavage N-terminus; parent mass tolerance 30 ppm; fragment mass tolerance 0.5 Da. Expectation value cut-off was adjusted to maintain <1% false-discovery rate at the peptide level in each sample. The analysis was performed using in-house scripts.

Results:

Rapid kinetics of cell death in response to Hsp70 inhibitors suggests that it has distinct clients. As a first step towards identifying clients important in Hsp70-mediated cell survival, we measured the kinetics of cell growth in response to the Hsp70 inhibitor, JG-98 (Fig 1a). In these experiments, we used MDA-MB-231 breast cancer cells, because they had previously been shown to be sensitive to Hsp70 inhibitors.14 Using MTT assays, we found that the growth of JG-98 treated MDA-MB-231 cells was reduced within 10 to 12 hours (Fig. 1b). In contrast, the response to the Hsp90 inhibitor, 17-DMAG, or the proteasome inhibitor, bortezomib, occurred over longer times, ~18 to 24 hours (Fig 1b). To confirm this result using a distinct cell growth measure, we also performed CellTiterGlo assays on treated MDA-MB-231 cells and found that the kinetics in response to multiple, different Hsp70 inhibitors: JG-98, JG-84, VER-155008 or MAL3-101, was markedly faster than treatment with Hsp90 inhibitors (Fig 1c). As mentioned above, it was important to note that Hsp70 inhibitors from multiple chemical series showed similar responses, giving confidence in the role of that target. It is well known that treatment with Hsp90 inhibitors leads to degradation of Hsp90 clients, such as Akt, Raf-1 and Cdk4, and that the kinetics of that process parallels cell death.28,29 To see if these same clients were involved in Hsp70-mediated cell proliferation, we performed Western blots on JG-98 treated lysates. Surprisingly, we found that it took ~12 to 24 hours for the levels of Akt, Raf-1 and Cdk4 to be reduced (Fig. 1d), which is relatively late into the response. This result suggested that the mechanism(s) of Hsp70 inhibitors might not be simply explained by "Hsp90-like" effects in these cells.
Inhibitors of Hsp70 induce apoptosis, independent of Bcl-xL status. To better understand the response to Hsp70 inhibition, we then asked whether treated MDA-MB-231 cells underwent apoptosis. This is an important step because MTT and CellTiterGlo assays primarily report on proliferation and not necessarily on cell death. Indeed, we found that JG-98 induced classical apoptosis features, including morphological changes consistent with programmed cell death (Fig S1a) and positive annexin staining (Fig S1b). This result is consistent with previous reports that JG-98 activates caspase cleavage\textsuperscript{14}. To further probe this idea, we overexpressed the Bcl-2 family member, Bcl-x\textsubscript{L}, a mitochondrial anti-apoptotic protein, in MDA-MB-231 cells. These cells are considered type II cells that undergo apoptosis through caspase-8 and the mitochondrial pathway\textsuperscript{30}, so high Bcl-x\textsubscript{L} levels would be expected to block JG-98-mediated cell death. Importantly, we also performed parallel studies in leukemia-derived Jurkat cells, because it is known that over-expression of Bcl-x\textsubscript{L} only incompletely inhibits RIP1-dependendent cell death in MDA-MB-231 cells\textsuperscript{27}. Surprisingly, we found that overexpression of Bcl-x\textsubscript{L} did not impede cytotoxicity in response to JG-98 in either cell type (Figs. 2a, b). As controls, we confirmed that Bcl-x\textsubscript{L} overexpression partially suppressed cell death in response to the control molecules, 17-DMAG, bortezomib or etoposide, in either MDA-MB-231 (see Fig 2a) or Jurkat (see Fig 2b) cells. To understand the impact of Bcl-x\textsubscript{L} over-expression on the potency of the compounds, we performed dose dependence studies in MDA-MB-231 cells and calculated EC\textsubscript{50} values. Consistent with the single concentration data, we found that over-expression of Bcl-x\textsubscript{L} did not alter the EC\textsubscript{50} for JG-98 (Fig 2c); whereas the EC\textsubscript{50} of 17-DMAG, bortezomib and etoposide were significantly increased (2.5- to 5.7-fold). The mechanism of cell death did not seem to be affected, because treatment of the Bcl-xL overexpressing cells with JG-98 led to morphological features that were still consistent with apoptosis (Fig. S2a). Based on the mitochondrial retention of COX IV in treated MDA-MB-231 cells, this apoptotic activity also seemed to occur without global disruption of mitochondria (Fig S2b). Thus, inhibition of Hsp70 appeared to initiate a mitochondrial death pathway that was independent of Bcl-2 family status.
When caspase-mediated apoptosis is blocked, Hsp70 inhibitors trigger an alternative, necroptosis pathway. The caspase inhibitor, z-VAD.fmk, is known to partially suppress cell death in response to Hsp90 inhibitors. However, we found that this compound did not block proliferation induced by JG-98 (Fig. 3a). Rather, we observed that 51 ± 13% cells pre-treated with z-VAD.fmk before addition of JG-98 displayed a swollen cytoplasm containing numerous granules (Fig. 3b). This morphology was not observed in the absence of v-VAD.fmk. The swollen cytoplasm feature is reminiscent of necrotic cell death, suggesting that JG-98 might be activating an alternative pathway if apoptosis was blocked. Consistent with this idea, we observed nuclear fragmentation in only 4 ± 1% of cells that were pre-treated with z-VAD.fmk prior to JG-98, compared to 40 ± 16% in the absence of z-VAD.fmk (Fig. 3c). To further explore whether JG-98 might be activating an alternative death pathway, we profiled the peptide fragments produced from proteolysis in cells treated with JG-98, using a recently described mass spectrometry-based method termed “N-terminal degradomics” (Fig 4a). Briefly, this method profiles the neo peptide termini that are produced by proteolysis during cell death. Treatment of Jurkat cells with JG-98 produced a fragment profile consistent with caspase activation, as judged by the prominent aspartate in the P1 position (Fig 4b,c and Table S1). As expected, treatment with z-VAD.fmk nearly completely blocked this signature. Moreover, when z-VAD.fmk was used as a co-treatment with JG-98, it also suppressed the caspase response (Fig 4b,c), with the peptide profile resembling the untreated cells. These results support the idea that treatment with JG-98 initiates caspase-mediated apoptosis, but that the cells die by an alternative, necroptosis, pathway when caspases are inhibited. Perhaps more broadly, these findings also show that necroptosis occurs in the absence of dramatic proteolysis, a feature of this alternative cell death pathway that had not previously been described.

Hsp70 limits RIP1 activation by stabilizing E3 ligases. RIP1 is an important signaling regulator that directs cells into either the apoptotic or necroptotic cascades. Because JG-98 appeared to initiate both pathways, we hypothesized that RIP1 might be important in Hsp70-mediated cell survival. To test this idea, we treated Jurkat cells lacking RIP1. Strikingly, JG-98 was not cytotoxic in RIP1 knockout Jurkat cells (Fig. 5a).
Similarly, necrostatin-1, an inhibitor of RIP1’s kinase activity\textsuperscript{34}, protected MDA-MB-231 cells from treatment with JG-98 (Figs. 5b). Conversely, treatment with 17-DMAG, bortezomib or etoposide was not affected by loss of RIP1 protein or RIP1 activity (see Figs 5a,b). Thus, cell death by JG-98 appeared to be uniquely dependent on RIP1 kinase activity. RIP1 is constitutively ubiquitinated by the E3 ubiquitin ligases XIAP, c-IAP1, c-IAP2, and cFLIP\textsubscript{S/L}\textsuperscript{35}. Ubiquitination of RIP1 is linked to turnover of the kinase, but also to non-degradation pathways that modulate RIP1 activity\textsuperscript{36}. Indeed, ubiquitination of RIP1 is thought to protect against necroptosis\textsuperscript{37}. Hsp70 is known to protect a number of proteins from degradation, so it seems possible that it may normally stabilize RIP1 itself or the E3 ligases. To test this idea, we treated MDA-MB-231 cells with JG-98 and examined the levels of RIP1 and its E3 ligases by Western blots. Although inhibition of Hsp70 did not significantly impact RIP1 protein levels under these conditions, it induced a striking loss of XIAP, c-IAP1\textsubscript{2} and cFLIP\textsubscript{S/L} (Fig. 5c). To test whether this pathway might be linked to JG-98 treatment, we examined the kinetics by which the levels of c-IAP, XIAP and cFLIP\textsubscript{S/L} are reduced. Indeed, loss of the E3 ubiquitin ligases closely paralleled the kinetics of cell death, with cFLIP\textsubscript{S} levels diminished within 1 to 3 hours and the levels of the other ligases beginning to decrease between 6 and 12 hours (Fig. 5d). This result sharply contrasts with the delay in Hsp90 client destabilization that we observed earlier (see Fig. 1b), suggesting that Hsp70 regulation of RIP1 may be more closely linked to activity in these cells. To understand the mechanism of turnover, we deleted the RING domain from XIAP (XIAP\textsubscript{ARING}) and compared its stability to full length XIAP (XIAP\textsubscript{FL}) in the presence of JG-98 in MDA-MB-231 cells (Fig S3a). XIAP is known to degraded by self-ubiquitination through this domain\textsuperscript{38,39}. We found that XIAP\textsubscript{ARING} was resistant to treatment with JG-98 (Fig S3b), consistent with activation of its normal turnover pathway through the ubiquitin proteasome system. Finally, we wanted to test whether Hsp70 inhibitors from different structural classes also trigger loss of the E3 ligases. These types of experiments are important for confirming on-target activity because, as mentioned above, the different inhibitors have distinct chemical structures and they bind different allosteric sites on the chaperone\textsuperscript{15}. Indeed, we found that treatment with JG-84, VER-155008 or MAL3-101...
also destabilized c-IAP1 in MDA-MB-231 cells, while a structurally-related negative control, JG-258, had no effect (Fig S3c).

**Blocking caspase-mediated apoptosis and necroptosis prevents cell death in response to Hsp70 inhibitors.** Next, we wondered whether blocking necroptosis would make cells resistant to JG-98. However, we found that inhibition of this pathway by necrosulfonamide (NSA) did not block JG-98 effects on proliferation (Fig 6a). Further, the proteolytic fragment signature of these treated cells suggested that they may still die by caspase-mediated apoptosis (see Fig 4d). Then, to understand if blocking both apoptosis and necroptosis might limit JG-98 mediated activity, we pre-treated MDA-MB-231 (Fig 6b) or Jurkat cells (Fig 6c) with both z-VAD.fmk and NSA. We found that the combination partially blocked JG-98-mediated cell death. Importantly, a distinct Hsp70 inhibitor, VER-155008, also required co-treatment with both z-VAD-fmk and NSA to protect against activity in MDA-MB-231 cells (Fig S4a). To explore this phenomenon more broadly, we tested JG-98 in combination with v-VAD.fmk or z-VAD.fmk plus NSA in cancer cells derived from a variety of tissues. Consistent with the results from the MDA-MB-231 and Jurkat cells, z-VAD.fmk alone was unable to protect cells derived from breast (MCF7, SK-BR-3, T-47D), lung (A549) or colon (HT-29) (Fig S4b), while cervical-derived HeLa cells were partially protected (EC$_{50}$ increased 2-fold). Next, we used the combination of z-VAD.fmk and NSA and found that both were required to protect MDA-MCF7, SK-BR-3 and Jurkat cells. Interestingly, A549, T47-D and HT-29 cells were not fully protected by this combination and the effect of JG-98 may have even been mildly exacerbated (see Fig S4b). These results suggest that Hsp70 may play additional roles in some cell types, perhaps through additional mechanisms such as lysosomal cell death$^{40}$.

**Hsp70 blocks oligomerization and activation of RIP1.** Finally, we wanted to explore additional, possible mechanisms by which Hsp70 could inhibit RIP1 activation. One major role for RIP1 is as a central scaffold in the TNF-Receptor 1 (TNF-R1) complex$^{33}$. It has been shown that autocrine-TNF-producing cells, such as MDA-MB-231, are sensitive to small molecule mimetics of the Smac/DIABLO protein and that this
cytotoxicity proceeds through TNF-R1\textsuperscript{27}. We investigated this possibility for JG-98, and found that a neutralizing antibody against TNF-R1 (Enbrel) blocked cell death by a Smac mimetic (SM), but that it was unable to prevent JG-98 induced cell death (Fig. 7a). Thus, JG-98 appears to act independently of TNF-R1, but with a mechanism distinct from Smac mimetics. A cytosolic death complex containing RIP1, termed the ripoptosome, has been also shown to direct both apoptosis and necroptosis\textsuperscript{27}. A key event in formation of the ripoptosome is binding of RIP1 to caspase-8. To determine if treatment with JG-98 triggered this event, we immunoprecipitated caspase-8 and performed Western blots with a RIP1 antibody. While Smac mimetic gave the expected result, JG-98 did not promote the interaction (Fig. 7b), suggesting that JG-98 does not trigger formation of the ripoptosome. Lastly, we tested whether Hsp70 might play a role in RIP1 oligomerization. It has recently been reported that RIP1 and RIP3 forms stable, oligomeric, amyloid-like structures that are required for necroptosis\textsuperscript{41}, which appear as stable, high molecular mass bands on SDS-PAGE. At the same time, it is well known that Hsp70 broadly inhibits the formation of amyloids formed from diverse proteins, such as amyloid beta, huntingtin and tau\textsuperscript{42}. Thus, it seemed logical that Hsp70 might counteract conversion of RIP1 into its amyloid state, such that treatment with JG-98 might relieve this suppression. To test this idea, we treated MDA-MB-231 cells with JG-98 or the combination of JG-98 and z-VAD.fmkk (to induce necroptosis) and looked for stable, high molecular mass oligomers of RIP1. We found that treatment with JG-98 promoted conversion of RIP1 to the oligomeric state, concurrent with depletion of its binding partner, RIP3 (Fig 7c). Similar effects were observed with the other Hsp70 inhibitors, JG-84 and VER-155008 (Fig S5). Again, this mechanism was distinct from that used by SM-164, which had no effect on RIP1 oligomerization in this system (see Fig 7d). Further, RIP1 oligomerization did require kinase activity in this context, as Nec-1 could block the process. Importantly, treatment with 17-DMAG or bortezomib did not impact RIP1 oligomerization (Fig 7d). Together, these results suggested that Hsp70 plays a key role in suppressing RIP1 activation, possibly through effects on the stability of its E3 ligases and on its self-association.

Discussion
Knockdown of Hsp70 has been shown to reduce proliferation and enhance sensitivity to chemotherapy in multiple cancer models\(^1\)\(^-\)\(^4\). Because Hsp70 itself is not an oncogene, it was presumed that it acts through a “non-oncogene addiction” mechanism, in which the chaperone stabilizes a subset of oncogenes to protect against cell death\(^6\)\(^,\)\(^43\). Hsp90 is known to play a similar functional role\(^12\), yet more is known about the mechanisms by which that chaperone creates a non-oncogene addiction. Specifically, Hsp90 is known to directly bind and stabilize a subset of pro-survival clients, including Akt, Her-2, Raf-1 and cdk4\(^44\). Although individual clients of Hsp70 have been suggested\(^6\)\(^-\)\(^8\) and some shared clients seem likely\(^45\), we wondered whether these two chaperones might also have distinct clients. This question became possible to address, thanks to the recent development of Hsp70 inhibitors by multiple research groups. By analogy, the clients of Hsp90 were revealed after the serendipitous discovery of geldanamycin and the development of its more potent analogs, such as 17-DMAG\(^46\). Thus, given recent advances in Hsp70 inhibitor discovery, it seemed timely to ask whether Hsp70 might have its own clients. Here, we used a suite of Hsp70 inhibitors with different binding sites and mechanisms to explore Hsp70’s pro-survival function. We focused on MDA-MB-231 and Jurkat cells, because of existing genetic data on the importance of Hsp70 in these cells, but it is important to stress that Hsp70 may play additional roles in other cells (see Fig S4B).

Our results suggest an unexpected model in which Hsp70 protects against cell death through suppressing RIP1 activation. In part, this mechanism appears to involve Hsp70-mediated stabilization of the E3 ubiquitin ligases of RIP1, such as c-IAPs and XIAP (see Fig 5). Importantly, we found that the kinetics of cell death correlate better with loss of these E3 ligases than with the turnover of the classical Hsp90 clients, such as Raf-1. This result could be particularly important for the future of Hsp70 inhibitor development, as these E3 ligases might be biomarkers for Hsp70 engagement. Again, an analogy to Hsp90 is illuminating because loss of the Hsp90 clients, such as Raf-1 and Akt, is often used to estimate engagement of that target. Another mechanism of Hsp70-mediated cell survival appeared to involve suppression of RIP1/3 amyloid
formation. Specifically, we found that treatment with JG-98 or other Hsp70 inhibitors relieved this suppression and allowed RIP1 oligomers to form (see Fig 7). In retrospect, this finding might have been expected, based on the widespread role of Hsp70 in preventing amyloid formation\(^47\). Although this mechanism has been best described in the neurodegenerative disease literature, it seems logical that it would also play this part in cancer.

Hsp70 has been linked to a wide number of cell survival aspects. We hypothesize that some of these activities might be consolidated and understood through the functions on RIP1, a key, upstream “hub” of multiple cell death pathways. Indeed, our results suggest that, at least in MDA-MB-231 and Jurkat cells, this mechanism might be particularly important because RIP1 knockdown or co-treatment with necrostatin was sufficient to completely suppress JG-98’s activity. However, many important mysteries remain. For example, we observed that cell death in response to Hsp70 inhibitor was independent of Bcl-x\(^\text{L}\) and it was coupled with an unusual relationship to cytochrome c release. Further, it has been shown that RIP1 itself is a client of Hsp90\(^48\) and that Hsp90 inhibitors can impact necroptosis in fibrosarcoma cells\(^49\). Thus, it seems compelling to envision that Hsp90 and Hsp70 may cooperate in suppressing the RIP1 pathway, in a currently unknown way. It is even possible that combinations of Hsp70 and Hsp90 inhibitors could be synergistic in this setting.

Finally, this work may accelerate the search for drug candidates that target Hsp70. Based on expression data, biochemical studies and knockdowns, members of the Hsp70 family appear to be compelling, potential drug targets\(^50,51\). However, progress has been slowed by lack of mechanistic knowledge. Our results are potentially important in that context because they suggest that IAP family members may be biomarkers of Hsp70 inhibition. If that finding is found to be robust across many cell types and by different groups, it would be expected to boost efforts to discover, optimize and deploy clinical candidates to test the central hypothesis of Hsp70 as an anti-cancer target.
References


46 Schulte, T. W. & Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities


Figure Legends

Figure 1. Inhibition of Hsp70 Causes Rapid Anti-Proliferative Activity. (A) Chemical structures of Hsp70 inhibitors (JG-98, JG-84, MAL3-101 and VER-155008), controls (JG-258) and inhibitors of Hsp90 (17-DMAG) and the proteasome (bortezomib). (B) JG-98 (5 µM) suppress growth of MDA-MB-231 cancer cells with relatively rapid kinetics compared to 17-DMAG (5 µM) or bortezomib (40 nM), as monitored by MTT assays. Results are the average of two independent experiments performed in quintuplicates. The error bars represent the standard error of the mean (SEM). (C) Hsp70 inhibitors induce rapid cell growth effects, as measured by Cell Titer Glo. Results are the average of experiments performed in triplicate. Errors are SEM. (D) Chaperone clients are degraded relatively late after treatment with JG-98 (10 µM), after onset of effects on cell growth. Results are representative of experiments performed in duplicate.

Figure 2. Hsp70 Inhibitor Activity is Independent of Bcl Status. (A) Overexpression of Bcl-xL does not block JG-98 cytotoxicity. MDA-MB-231 cells were treated for 24 hrs with JG-98 (10 µM), 17-DMAG (10 µM), bortezomib (40 nM) or etoposide (20 µM). MTT results are the mean average of triplicates and error bars represent SEM. *p value <
0.05. (B) Jurkat cells over-expressing Bcl-xL were treated with indicated compounds for 24 hours. Viability was determined by trypan blue staining. Results are the average of two experiments performed in triplicate. Error is SEM. **p value < 0.01. (C) Bcl-xL overexpression provides partial resistance to compounds, except JG-98. MDA-MB-231 cells were treated for 72 hours and cell growth determined by MTT assays. Results are the average of two independent experiments performed in triplicate. Error is SEM.

**Figure 3. Inhibition of Caspases with z-VAD-fmk Does not Block JG-98’s Activity.** (A) Inhibition of caspases by z-VAD.fmk does not suppress the activity of JG-98. Results are the average of three independent experiments performed in quintuplicate. Error bars represent SEM. Cells were pretreated with z-VAD.fmk (40 μM) for 1 hour prior to addition of compounds (same concentrations as in panel A) and MTT assays performed after 24 hrs. **p value < 0.01. ns = not significant. Error is SEM. (B) Cells were treated as in panel A and visualized using an Olympus IX83 Inverted Microscope. Black arrows indicate apoptotic cells; white arrows indicate necrotic cells. (C) Hoechst 33258 staining of MDA-MB-231 cells pretreated with z-VAD.fmk (40 µM) for 1 hour prior to addition of JG-98 (10 µM) for 24 hours. Cells pre-treated with z-VAD.fmk show no nuclear fragmentation (white arrows), even after co-administration of JG-98. Scale bar is 10 µm.

**Figure 4. Proteolytic Signature of Cells Treated with JG-98 Supports Activation of Both an Apoptotic and Alternative Cell Death Pathway.** (A) Schematic overview of the proteolytic profiling study (aka “N-terminal degradomics”). (B) Overview of the peptide fragments produced in response to compound treatments. More than 45% of the substrates identified after JG-98 treatment feature a P1 = D, suggesting the activation of caspases. In general, there was minimal proteolysis in untreated cells or cells treated with JG-98 and z-VAD. Aminobutyric acid (Abu). (C) Logo plots show that JG-98 activates apoptosis in Jurkat cells and NSA is unable to block this activity. However, z-VAD reversed the proteolytic profile to one that approximated untreated cells. (D) The caspase activation profile (P1=D peptides) was similar between cells treated with JG-98 or JG-98 plus NSA, while the pattern of peptides (P1 = all) was similar between JG98 +
zVAD and untreated cells. Experiments repeated in biological duplicate and technical triplicate.

**Figure 5.** *JG-98 Activity Occurs through a RIP1-Dependent Process.* (A) RIP1 KO Jurkat cells are resistant to JG-98. Viability was determined by trypan blue exclusion. Cells were treated for 24 hrs with JG-98 (10 µM), 17-DMAG (10 µM), bortezomib (40 nM), etoposide (20 µM). Results are the average of three independent experiments performed in triplicate. ns = not significant; * p < 0.05. (B) JG-98 activity requires RIP1 kinase. MDA-MB-231 cells were pretreated with 20 µM necrostatin-1 for 1 hour prior to addition of compounds. Viability was determined by three independent MTT assays performed in quintuplicate. Error is SEM. ns = not significant; ***p < 0.0001. (C) JG-98 induces degradation of RIP1 modulators. MDA-MB-231 cells were treated for 24 hours. Results represent experiments performed in triplicate. (D) RIP1 regulators are rapidly degraded in response to JG-98. MDA-MB-231 cells were treated with JG-98 (10 µM). Results are representative of duplicates.

**Figure 6.** *JG-98 Activity Requires Both Apoptosis and Necroptosis.* (A) Inhibition of necroptosis alone does not restore growth of cells treated with JG-98. Cells were pretreated with necrosulfonamide (NSA, 20 µM) for 1 hour prior to addition of compounds. Error is SEM. (B) Inhibition of both apoptosis and necroptosis is necessary to fully suppress JG-98 activity. Cells were pretreated with both 40 µM z-VAD.fmk and 20 µM Necrosulfonamide for 1 hour prior to addition of compounds. Cell growth was determined by three independent MTT assays performed in quintuplicate. *p value < 0.05, **p value < 0.01, ***p value < 0.001, ns = not significant. (C) Jurkat cells were pretreated with z-VAD.fmk (40 µM), NSA, both, or necrostatin-1 for 1 hour prior to addition of JG-98 (10 µM). Inactivation of both apoptosis and necroptosis was necessary to prevent activity. Cell viability was determined by trypan blue exclusion. Results are the average of three independent experiments performed in triplicate.
Figure 7. Hsp70 Limits RIP1/3 Oligomerization. (A) JG-98 toxicity does not depend on TNF signaling. MDA-MB-231 cells were pre-treated with Enbrel (5 µg/mL) for 1 hour prior to addition of compounds. Viability was determined by MTT assay. Results are the average of three independent experiments performed in quintuplicate. Error is SEM. **p value < 0.01 (B) JG-98 does not induce formation of a RIP1-caspase-8 complex. MDA-MB-231 cells were treated for 24 hours with indicated compounds. SM-164 was used at 100 nM. (C) Treatment with JG-98 (10 µM) favored formation of a high molecular mass oligomer of RIP1 and a reduction of RIP3. Co-treatment with z-VAD-fmk exacerbated this effect. Necrostatin could block the effects of JG-98. Results are representative of experiments performed in triplicate. (D) Treatment with 17-DMAG or bortezomib (BTZ) did not change RIP1 oligomerization.

Disclosure of Potential Conflicts of Interest
The authors claim no competing financial interests.

Author’s Contributions
S.R.S, X.L., O.J., M.Z., L.C.C., H.S. and J.C. conceived, designed and performed experiments. I.M., J.A.W., C.D. and J.E.G. conceived, designed and supervised the project. All of the authors contributed to writing the manuscript.

Acknowledgements
The authors would like to thank the members of the Gestwicki and Duckett labs for assistance. MAL3-101 was supplied by Jeff Brodsky (U. Pittsburgh).

Grant Support
Funding for this work was provided by the NIH (NS095690) and the University of Michigan’s Comprehensive Cancer Center (CA046592).

Supplementary Information
Figs. S1, S2, S3, S4, S5 and Table S1 are available.
Figure 1
(A) JG-98 retains activity after Bcl-xL overexpression

(B) Bcl-xL overexpression does not block JG-98 activity in Jurkat cells

(C) Bcl-xL does not alter JG-98’s potency in MDA-MB-231 cells

<table>
<thead>
<tr>
<th>vector</th>
<th>JG-98 (EC_{50} nM)</th>
<th>17-DMAG</th>
<th>bortezomib</th>
<th>etoposide</th>
</tr>
</thead>
<tbody>
<tr>
<td>empty</td>
<td>450 ± 88</td>
<td>24 ± 6.3</td>
<td>290 ± 69</td>
<td>5300 ± 600</td>
</tr>
<tr>
<td>Bcl-xL</td>
<td>420 ± 84</td>
<td>136 ± 28</td>
<td>740 ± 170</td>
<td>25000 ± 6700</td>
</tr>
<tr>
<td>fold change</td>
<td>0.9</td>
<td>5.7</td>
<td>2.5</td>
<td>4.7</td>
</tr>
</tbody>
</table>
Figure 3

(A) Inhibition of caspases does not block JG-98 activity

(B) JG-98 induces necrosis when apoptosis is blocked

(C) z-VAD.fmk prevents nuclear fragmentation in response to JG-98 in MDA-MB-231 cells
(A) Schematic of the global proteolysis experiment

(B) Necroptosis does not involve proteolysis

(C) Necroptosis does not involve caspase activation

(D) P1 peptide analysis

Figure 4
Figure 5
Figure 6
Figure 7

(A) JG-98 cytotoxicity does not depend on TNF-R1

<table>
<thead>
<tr>
<th></th>
<th>DMSO</th>
<th>Enbrel</th>
</tr>
</thead>
<tbody>
<tr>
<td>JG-98</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17-DMAG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bortezomib</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SM-164</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(B) JG-98 does not promote RIP1 interaction with caspase-8

<table>
<thead>
<tr>
<th></th>
<th>5% input</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td></td>
</tr>
<tr>
<td>JG-98</td>
<td></td>
</tr>
<tr>
<td>17-DMAG</td>
<td></td>
</tr>
<tr>
<td>Bortezomib</td>
<td></td>
</tr>
<tr>
<td>SM-164</td>
<td></td>
</tr>
</tbody>
</table>

(C) Inhibition of Hsp70 promotes RIP1/3 oligomers

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>JG-98</td>
<td>-</td>
</tr>
<tr>
<td>z-VAD-fmk</td>
<td>-</td>
</tr>
<tr>
<td>Nec-1</td>
<td>-</td>
</tr>
<tr>
<td>SM-164</td>
<td>-</td>
</tr>
</tbody>
</table>

(D) Inhibitors of Hsp90 and proteasome do not promote RIP1 oligomerization

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>JG-98</td>
<td>-</td>
</tr>
<tr>
<td>17-DMAG</td>
<td>-</td>
</tr>
<tr>
<td>BTZ</td>
<td>-</td>
</tr>
<tr>
<td>z-VAD-fmk</td>
<td>-</td>
</tr>
</tbody>
</table>

210 kDa 140 kDa 70 kDa

RIP1

actin

210 kDa 140 kDa 70 kDa

RIP1

actin
Molecular Cancer Research

Heat Shock Protein 70 (Hsp70) Suppresses RIP1-dependent Apoptotic and Necroptotic Cascades

Sharan R Srinivasan, Laura C Cesa, Xiaokai Li, et al.

Mol Cancer Res Published OnlineFirst September 28, 2017.

Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-17-0408

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mcr.aacrjournals.org/content/early/2017/09/28/1541-7786.MCR-17-0408. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.